Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marko Lucijanic

Showing results (1-10 of 139) with videos related to

Pageof 14
Sort By:
The New England Journal of Medicine|November 18, 2020
Azacitidine and Venetoclax in AMLMarko Lucijanic
Annals of Hematology|June 20, 2020
Progressive multifocal leukoencephalopathy during rituximab maintenance after rituximab and bendamustine treatment for relapsed follicular lymphomaMarko Lucijanic, Ozren Jaksic
Journal of Medical Virology|July 7, 2021
Remdesivir might induce changes in electrocardiogram beyond bradycardia in patients with coronavirus disease 2019-The pilot studyPetra Bistrovic, Marko Lucijanic
British Journal of Haematology|May 3, 2019
Could haemochromatosis (HFE) gene mutations affect response to iron chelation in myelodysplastic syndrome?Marko Lucijanic, Rajko Kusec
Kidney International|March 22, 2024
Cytoreductive treatment and kidney vascular damage in patients with chronic myeloproliferative neoplasmsIvan Krecak, Marko Lucijanic
Journal of Thrombosis and Thrombolysis|February 6, 2023
Chronic kidney disease and thrombotic risk in patients with chronic myeloproliferative neoplasmsMarko Lucijanic, Ivan Krecak
The Lancet. Haematology|November 5, 2025
Can ropeginterferon SURPASS resistance in essential thrombocythaemia?Marko Lucijanic, Ivan Krecak
Clinical Lymphoma, Myeloma & Leukemia|May 1, 2019
Platelet Counts and Risk of Major Bleeding With IbrutinibMarko Lucijanic, Marko Skelin
European Journal of Internal Medicine|May 9, 2023
Pulmonary embolism, is it healthy to be volume expanded?Marko Lucijanic, Ivan Krecak
JACC. Cardiooncology|January 11, 2024
Prognosis of MPN Patients Experiencing Acute Thrombotic Events and the Potential Role of CytoreductionIvan Krecak, Marko Lucijanic
Pageof 14

Showing results (1-10 of 139) with videos related to

Sort By:
Pageof 14
The New England Journal of Medicine|November 18, 2020
Azacitidine and Venetoclax in AMLMarko Lucijanic
Annals of Hematology|June 20, 2020
Progressive multifocal leukoencephalopathy during rituximab maintenance after rituximab and bendamustine treatment for relapsed follicular lymphomaMarko Lucijanic, Ozren Jaksic
Journal of Medical Virology|July 7, 2021
Remdesivir might induce changes in electrocardiogram beyond bradycardia in patients with coronavirus disease 2019-The pilot studyPetra Bistrovic, Marko Lucijanic
British Journal of Haematology|May 3, 2019
Could haemochromatosis (HFE) gene mutations affect response to iron chelation in myelodysplastic syndrome?Marko Lucijanic, Rajko Kusec
Kidney International|March 22, 2024
Cytoreductive treatment and kidney vascular damage in patients with chronic myeloproliferative neoplasmsIvan Krecak, Marko Lucijanic
Journal of Thrombosis and Thrombolysis|February 6, 2023
Chronic kidney disease and thrombotic risk in patients with chronic myeloproliferative neoplasmsMarko Lucijanic, Ivan Krecak
The Lancet. Haematology|November 5, 2025
Can ropeginterferon SURPASS resistance in essential thrombocythaemia?Marko Lucijanic, Ivan Krecak
Clinical Lymphoma, Myeloma & Leukemia|May 1, 2019
Platelet Counts and Risk of Major Bleeding With IbrutinibMarko Lucijanic, Marko Skelin
European Journal of Internal Medicine|May 9, 2023
Pulmonary embolism, is it healthy to be volume expanded?Marko Lucijanic, Ivan Krecak
JACC. Cardiooncology|January 11, 2024
Prognosis of MPN Patients Experiencing Acute Thrombotic Events and the Potential Role of CytoreductionIvan Krecak, Marko Lucijanic
Pageof 14